Maven Securities’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-16,300
Closed -$922K 802
2024
Q4
$922K Buy
+16,300
New +$911K 0.02% 434
2023
Q2
Sell
-8,200
Closed -$568K 878
2023
Q1
$568K Sell
8,200
-17,100
-68% -$1.21M 0.01% 620
2022
Q4
$1.82M Sell
25,300
-14,600
-37% -$1.1M 0.04% 275
2022
Q3
$2.84M Sell
39,900
-19,500
-33% -$1.41M 0.05% 223
2022
Q2
$4.57M Buy
59,400
+20,900
+54% +$1.59M 0.14% 113
2022
Q1
$2.81M Buy
38,500
+5,800
+18% +$389K 0.1% 133
2021
Q4
$2.04M Buy
32,700
+8,700
+36% +$510K 0.06% 190
2021
Q3
$1.42M Sell
24,000
-24,600
-51% -$1.62M 0.05% 330
2021
Q2
$3.25M Buy
48,600
+44,200
+1,005% +$2.88M 0.13% 135
2021
Q1
$278K Buy
+4,400
New +$274K 0.01% 828

Other funds holding BMY

Maven Securities's BMY Position: Q1 2025 in Review

Maven Securities sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 16,688 shares — an estimated $944K sold.

Maven Securities first reported a position in BMY in Q2 2021 and held it in 8 quarters. The position peaked at $1.83M in Q3 2022. 2,477 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

  • Maven Securities reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
  • Maven Securities sold 16,688 Bristol-Myers Squibb shares in Q1 2025, an estimated $944K.
  • Maven Securities first reported a position in Bristol-Myers Squibb in Q2 2021 and held it in 8 quarters.
  • Maven Securities's Bristol-Myers Squibb position peaked at $1.83M in Q3 2022.
  • 2,477 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Maven Securities's 13F filing for Q1 2025, filed 14 May 2025.